Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

TELA Bio (TELA) EBITDA Margin (2018 - 2025)

TELA Bio (TELA) has 8 years of EBITDA Margin data on record, last reported at 41.59% in Q3 2025.

  • For Q3 2025, EBITDA Margin rose 1285.0% year-over-year to 41.59%; the TTM value through Sep 2025 reached 50.69%, up 978.0%, while the annual FY2024 figure was 54.61%, 2533.0% up from the prior year.
  • EBITDA Margin reached 41.59% in Q3 2025 per TELA's latest filing, up from 49.12% in the prior quarter.
  • Across five years, EBITDA Margin topped out at 34.06% in Q1 2024 and bottomed at 123.69% in Q1 2021.
  • Average EBITDA Margin over 5 years is 78.19%, with a median of 78.3% recorded in 2024.
  • Peak YoY movement for EBITDA Margin: surged 6936bps in 2021, then crashed -2676bps in 2025.
  • A 5-year view of EBITDA Margin shows it stood at 91.4% in 2021, then rose by 11bps to 81.22% in 2022, then rose by 6bps to 76.09% in 2023, then surged by 31bps to 52.51% in 2024, then rose by 21bps to 41.59% in 2025.
  • Per Business Quant database, its latest 3 readings for EBITDA Margin were 41.59% in Q3 2025, 49.12% in Q2 2025, and 60.82% in Q1 2025.